"What I don’t understand is how there hasn’t been publication of clear data showing the efficacy of plasma when there has been a reported 60,000 people who have reportedly received the treatment"

That happens when you over-enroll open-label, non-randomized studies by 300% or more, and fail to conduct appropriate studies...

FDA should have asked to stop enrollment in those trials (similar to what they did with our eINDs) and asked for double-blind, placebo-controlled studies...